Colossal Biosciences CEO and co-founder Ben Lamm gets the Jurassic Park comparison. When your company is trying to bring back ...

Colossal Biosciences CEO and co-founder Ben Lamm gets the "Jurassic Park" comparison. When your company is trying to bring back the woolly mammoth, it’s only natural that people compare it ...

Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on ...

The study found that Prequel ® Prenatal Screen with AMPLIFY™ technology enables reliable results as early as eight-weeks’ gestation. Typically, prenatal cell-free DNA (pcfDNA) screening is offered ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at ...

Check Out Our Latest Research Report on MYGN Myriad Genetics Trading Up 3.9 % Shares of NASDAQ:MYGN opened at $12.76 on Thursday. The company has a current ratio of 1.90, a quick ratio of 1.73 and ...

We recently compiled a list of the Billionaire Larry Robbins’ Long-Term Stock Picks. In this article, we are going to take a ...

In this article, we are going to take a look at where Myriad Genetics, Inc. (NASDAQ:MYGN) stands against Larry Robbins' other long-term stock picks. Larry Robbins is an American hedge fund manager ...

Myriad Genetics, Inc. is a molecular diagnostic company, which focuses on developing and marketing of novel predictive and personalized medicines and prognostic medicine tests. It operates through ...

In this article, we are going to take a look at where Myriad Genetics, Inc. (NASDAQ ... This collaboration allows physicians to order Myriad’s MyRisk Hereditary Cancer Test and view the results ...

In this article, we are going to take a look at where Myriad Genetics, Inc. (NASDAQ:MYGN) stands against Larry Robbins’ other long-term stock picks. Larry Robbins is an American hedge fund ...